What plays a role in the choice of inhaler device for asthma therapy?

Current Medical Research and Opinion, Supplement

Volumn 21, Issue 4, 2005, Pages

  Virchow, J Christian ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

Asthma management; Chronic obstructive pulmonary disease; Drug delivery devices; Inhaler choice

Indexed keywords

ANTIASTHMATIC AGENT;

ACCURACY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; HUMAN; INHALER; INSPIRATORY CAPACITY; INTERMETHOD COMPARISON; MAINTENANCE THERAPY; METERED DOSE INHALER; POWDER INHALER; PRACTICE GUIDELINE;

ANTI-ASTHMATIC AGENTS; ASTHMA; NEBULIZERS AND VAPORIZERS; PATIENT COMPLIANCE;

EID: 25444470818     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X61758     Document Type: Conference Paper

References (36)

1. National Institute of Health, National Heart, Lung and Blood Institute. Global initiative for asthma - global strategy for asthma management and prevention. NHLI/WHO workshop report. NIH Publication Number 02-3659. October 2004
2. Clifford R, Radford M, Howell J, et al. Prevalence of respiratory symptoms among 7 and 11 year old school children and association with asthma. Arch Dis Child 1989;64:1118-25
3. von Mutius E, Fritzsch C, Weiland S, et al. Prevalence of asthma and allergic disorders among children in united Germany: a descriptive comparison. Br Med J 1992;305:1395-9
4. Robertson C, Heycock E, Bishop J, et al. Prevalence of asthma in Melbourne school children: changes over 26 years. Br Med J 1991;302:1116-8
5. Bronchial asthma. http://www.who.int/medica centre/fact sheets
6. Weissflog D, Matthys H, Virchow JC. Epidemiology and costs of bronchial asthma and chronic bronchitis in Germany. Dtsch Med Wochenschr 2001;126:803-8
7. Hanania N, Wittman R, Kesten S, Chapman K. Medical personnel's knowledge of an ability to use inhaling devices. Metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest 1994;105:111-6
8. Amirav I, Goren A, Pawlowski N. What do pediatricians in training know about the correct use of inhalers and spacer devices? J Allergy Clin Immunol 1994;94:669-75
9. British Thoracic Society. British guideline on the management of asthma [Scottish Intercollegiate Guidelines Network]. Thorax 2003;58(Suppl l):i1-94
10. Virchow JC, Kroegel C, Matthys H. Asthma drug delivery. What is on the horizon? Clin Pharmacokinet 1994;27:85-93
11. Pritchard J. The influence of lung deposition on clinical response. J Aerosol Med 2001;14(Suppl 1):S19-S26
12. Crompton G. Problems patients have using pressurized aerosol inhalers. Eur Respir Dis 1982;63(Suppl. 119):101-4
13. Newman S, Pitcairn G, Hirst P, et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J 2000;16:178-83
14. Newman S, Brown J, Steed K, Reader S, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest 1998;113:957-63
15. Pickering H, Pitcairn G, Hirst P, et al. Regional lung deposition of technetium 99m-labelled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered dose inhaler. Clin Ther 2000;22:1483-93
16. Ernst P. Inhaled drug delivery: a practical guide to prescribing inhaler devices. Can Respir J 1998;5:180-3
17. Kamps A, Brand P, Roorda R. Determinants of correct inhalation technique in children attending a hospital-based asthma clinic. Acta Paediatr 2002;91:159-63
18. Ruffin R, Campbell D, Chia M. Post-inhalation bronchoconstriction by beclomethasone dipropionate: a comparison of two different CFC propellant formulations in asthmatics. Respirology 2000;5:125-31
19. van der Palen J, Klein J, van Herwaarden C, Zielhuis G, Seydel E. Multiple inhalers confuse asthma patients. Eur Respir J 1999;14:1034-7
20. Rand C, Wise R, Nides M, et al. Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 1992;146:1559-64
21. Mann M, Eliasson O, Patel K, ZuWallack R. An evaluation of severity-modulated compliance with qid dosing of inhaled beclomethasone. Chest 1992;102:1342-6
22. Coutts J, Gibson N, Paton J. Measuring compliance with inhaled medication in asthma. Arch Dis Child 1992;67:332-3
23. Cerveri I, Locatelli F, Zoia M, et al. International variations in asthma treatment compliance: the results of the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1999;14:288-94
24. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996;98:1051-7
25. Kamps A, van Ewijk B, Roorda R, Brand P. Poor inhalation technique, even after inhalation instructions, in children with asthma. Pediatr Pulmonol 2000;29:39-42
26. Kamin W, Genz T, Roeder S, et al. The inhalation manager: a new computer-based device to assess inhalation technique and drug delivery to the patient. J Aerosol Med 2003;16:21-9
27. Bisgaard H. Delivery of inhaled medication to children. J Asthma 1997;34:443-67
28. Newhouse M. Pulmonary drug targeting with aerosols. Am J Asthma Allergy Pediatr 1993;7:23-5
29. Kohler D. The Novolizer: overcoming inherent problems of other dry powder inhalers. Respir Med 2004;98(Suppl A):S17-S21
30. Fyrnys B, et al. Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder inhaler device. Curr Opin Pulm Med 2001;7(Suppl 1):S7-S11
31. Berner B, et al. Asta Medica multidose dry powder inhaler. In: Daly R, Byron P, Farr S, editors. Respiratory drug delivery VI. Buffalo Grove (IL): Interpharm Press; 1998. p. 475-7
32. Pitcairn GR, Lankinen T, Seppälä OP, Newman SP. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort. J Aerosol Med 2000;13:97-104
33. Borgstrom L, Bondesson E, Moren F, et al. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994;7:69-73
34. Hirst P, Malik S, Antill C, et al. Interbronchial deposition of salbutamol in the human respiratory tract from the MAGhaler dry powder inhaler. Pharm Sci 1999;1:S-542
35. Pitcairn G, Lunghetti G, Ventura P, et al. A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler, at two inhaled flow rates. Int J Pharm 1994;102:11-8
36. Newman S, Hollingworth A, Clark A. Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int J Pharm 2004;102:127-32